<DOC>
	<DOCNO>NCT02024087</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability dalantercept plus sorafenib patient advance hepatocellular carcinoma ( HCC ) determine recommend dose level dalantercept combination sorafenib .</brief_summary>
	<brief_title>Study Dalantercept Sorafenib Patients With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Immunoglobulin Fc Fragments</mesh_term>
	<criteria>Histologically confirm , locally advanced metastatic HCC . ChildPugh Score A ( 56 ) At least one target lesion treat local therapy measurable Response Evaluation Criteria Solid Tumors ( RECIST ) v1.1 Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . Life expectancy least 12 week . Able tolerate oral therapy . Appropriate clinical laboratory value within 72 hour prior study day 1 : Females child bear potential ( define sexually mature woman undergone hysterectomy bilateral oophorectomy , naturally postmenopausal ≥ 24 consecutive month ) must negative urine blood pregnancy test prior enrollment use adequate birth control method ( abstinence , oral contraceptive , barrier method spermicide , surgical sterilization ) study participation . Males must agree use latex condom sexual contact female child bear potential participating study 12 week follow last dose dalantercept , even undergone successful vasectomy . Patients must counsel concern measure use prevent pregnancy potential toxicity prior first dose dalantercept . Mixed tumor histology Prior systemic therapy metastatic disease . Adjuvant therapy &lt; 6 month prior study day 1 . Prior treatment dalantercept agent target ALK1 pathway . Prior treatment sorafenib RAF/VEGF target therapy . Hepatic radiation , chemoembolization , radiofrequency ablation &lt; 4 week prior study day 1 . Palliative radiation therapy metastatic site disease &lt; 2 week prior study day 1 . Interferon therapy &lt; 4 week prior study day 1 . Uncontrolled Hepatitis B despite appropriate therapy . Clinically significant pulmonary , endocrine , neurologic , hematologic , gastrointestinal ( GI ) , autoimmune , psychiatric genitourinary disease unrelated HCC judgment investigator preclude treatment dalantercept sorafenib . Known HIV infection . Clinically significant cardiovascular risk Clinically significant active pulmonary risk Known active gastrointestinal ( GI ) bleeding . Known bleeding diathesis Known history hereditary hemorrhagic telangiectasia ( HHT ) . History another primary cancer , exception : 1 . Curatively resected non melanoma skin cancer . 2 . Curatively treated cervical carcinoma situ . 3 . Other primary solid tumor know active disease opinion investigator affect patient outcome set current HCC diagnosis . Major surgery within 4 week prior study day 1 Active infection Anticoagulation therapy Concomitant treatment potent CYP3A4 inducers Peripheral edema ≥ grade 2 within 2 week prior study day 1 . History recurrent ascites require paracentesis within 4 week study day 1 . History severe ( use National Cancer Institute Common Toxicity Criteria Adverse Events , version 4.0 [ NCICTCAE ] v4 current minor version ≥ grade 3 ) allergic anaphylactic reaction hypersensitivity recombinant proteins excipients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>